#1 Clinical Trials Search in Europe

Mr0005

This article explores the ongoing clinical trials of BEAM-302, an innovative gene therapy drug designed to treat Alpha-1 Antitrypsin Deficiency (AATD)-associated lung and liver diseases. BEAM-302 is being studied in a Phase 1/2 clinical trial to assess its safety, effectiveness, and optimal dosage in adult patients with AATD. The trial aims to provide valuable insights into this potential treatment option for individuals affected by this genetic disorder.

Table of Contents

What is BEAM-302?

BEAM-302 is an innovative gene therapy being developed to treat Alpha-1 Antitrypsin Deficiency (AATD), a genetic condition that can affect both the lungs and liver[1]. This experimental treatment is currently being studied in clinical trials to evaluate its safety and effectiveness in patients with AATD-associated lung and/or liver disease.

Target Condition: Alpha-1 Antitrypsin Deficiency (AATD)

Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic disorder that results in low levels of a protein called alpha-1 antitrypsin (AAT) in the blood[1]. This protein helps protect the lungs and liver from damage. People with AATD are at higher risk of developing lung diseases like emphysema and liver problems such as cirrhosis.

How BEAM-302 Works

BEAM-302 is designed to address the underlying genetic cause of AATD. It contains two key components:

  • MR0005: A therapeutic molecule that aims to correct the genetic mutation responsible for AATD
  • GR0015: Another component that works together with MR0005 to achieve the desired therapeutic effect

This gene therapy is administered through intravenous infusion, which means it’s delivered directly into the bloodstream[1]. The goal is to help the body produce normal, functional alpha-1 antitrypsin protein, potentially reducing the risk of lung and liver damage associated with AATD.

Clinical Trial Details

BEAM-302 is currently being studied in a Phase 1/2 clinical trial[1]. This trial has two main parts:

  1. Phase 1 (Dose Exploration): This part aims to evaluate the safety and tolerability of BEAM-302 and determine the optimal biological dose (OBD).
  2. Phase 2 (Dose Expansion): This part will further assess the effectiveness of BEAM-302 at the chosen dose.

The trial is open to adults aged 18-70 who have been diagnosed with AATD and have either lung or liver disease associated with the condition[1].

Potential Benefits

If successful, BEAM-302 could offer several potential benefits for patients with AATD:

  • Increased levels of functional alpha-1 antitrypsin in the blood
  • Reduced risk of lung damage and slowed progression of emphysema
  • Potential improvement in liver function and reduced risk of liver disease
  • A one-time treatment that could provide long-lasting benefits

Safety Considerations

As with any experimental treatment, there are potential risks and side effects to consider[1]. The clinical trial is designed to carefully monitor participants for any adverse events. Some safety measures include:

  • Careful screening of participants to ensure they meet specific health criteria
  • Close monitoring of liver and lung function throughout the study
  • Evaluation of the body’s immune response to the treatment
  • Long-term follow-up to assess the durability and safety of the treatment

Conclusion

BEAM-302 represents a promising new approach to treating Alpha-1 Antitrypsin Deficiency. While still in the early stages of clinical development, this gene therapy has the potential to address the root cause of AATD and improve outcomes for patients with both lung and liver manifestations of the disease. As research continues, more information will become available about the safety and effectiveness of this innovative treatment.

Aspect Details
Drug Name BEAM-302
Drug Type Gene Therapy
Administration Intravenous Infusion
Target Condition Alpha-1 Antitrypsin Deficiency (AATD)-Associated Lung and/or Liver Disease
Trial Phase Phase 1/2
Primary Objectives Evaluate safety, tolerability, and efficacy; Determine optimal biological dose
Key Inclusion Criteria Adults 18-70 years, AATD diagnosis, PiZ mutation, liver fibrosis, specific lung function criteria
Study Duration 15 years (including long-term extension)
Primary Endpoints Adverse event rates, Blood levels of total AAT, Z-AAT, and M-AAT

FAQ

  • What is BEAM-302? BEAM-302 is an experimental gene therapy drug being developed to treat Alpha-1 Antitrypsin Deficiency (AATD)-associated lung and liver diseases. It is administered through intravenous infusion and contains two active substances: MR0005 and GR0015.
  • Who can participate in the BEAM-302 clinical trial? The trial is open to adults aged 18-70 with a confirmed diagnosis of AATD who are homozygous for the PiZ mutation. Participants must have evidence of liver fibrosis and meet specific lung function criteria. The study has detailed inclusion and exclusion criteria to ensure participant safety and study validity.
  • What are the main objectives of the BEAM-302 clinical trial? The primary objectives are to evaluate the safety and tolerability of BEAM-302, determine the optimal biological dose, and assess its efficacy through pharmacodynamic activity in patients with AATD-associated lung and/or liver disease.
  • How long does the BEAM-302 clinical trial last? The total study participation is expected to last 15 years, including a long-term extension study. This extended duration allows researchers to thoroughly assess the long-term effects and safety of the treatment.
  • What are the potential benefits and risks of participating in the BEAM-302 trial? Potential benefits include access to a novel treatment for AATD and contributing to medical research. Risks may include treatment-related side effects, which will be closely monitored. The trial includes careful screening and monitoring to minimize risks to participants. As with any clinical trial, there may be unknown risks and benefits that will be discovered during the study.

Ongoing Clinical Trials on Mr0005

  • Study on the Safety and Effectiveness of BEAM-302 with MR0005 and GR0015 for Adults with Alpha-1 Antitrypsin Deficiency-Related Lung or Liver Disease

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Ireland The Netherlands

Glossary

  • Alpha-1 Antitrypsin Deficiency (AATD): A genetic disorder that can cause lung and liver disease due to low levels of a protein called alpha-1 antitrypsin in the blood.
  • Gene Therapy: A technique that uses genes to treat or prevent disease by introducing genetic material into a person's cells.
  • Pharmacodynamic (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Pharmacokinetic (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Optimal Biological Dose (OBD): The dose of a drug that produces the best balance between its therapeutic effects and side effects.
  • FEV1: Forced Expiratory Volume in 1 second, a measure of lung function used to assess the severity of lung disease.
  • Liver Fibrosis: Scarring of the liver tissue, which can occur in AATD and potentially lead to more severe liver disease.
  • METAVIR Score: A system used to assess the stage of liver fibrosis, with F1, F2, and F3 indicating increasing levels of fibrosis.
  • FibroScan: A non-invasive test used to assess liver stiffness and estimate the degree of liver fibrosis.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-beam-302-with-mr0005-and-gr0015-for-adults-with-alpha-1-antitrypsin-deficiency-related-lung-or-liver-disease/